These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12470210)

  • 1. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.
    Gabrielli BG; Johnstone RW; Saunders NA
    Curr Cancer Drug Targets; 2002 Dec; 2(4):337-53. PubMed ID: 12470210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors: anticancer compounds.
    Smith KT; Workman JL
    Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
    Abend A; Kehat I
    Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors in cancer therapy.
    Rasheed WK; Johnstone RW; Prince HM
    Expert Opin Investig Drugs; 2007 May; 16(5):659-78. PubMed ID: 17461739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: discovery and development as anticancer agents.
    Marks PA; Dokmanovic M
    Expert Opin Investig Drugs; 2005 Dec; 14(12):1497-511. PubMed ID: 16307490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.
    Gao Y; Zhang H; Lirussi F; Garrido C; Ye XY; Xie T
    Biochem Pharmacol; 2020 Dec; 182():114224. PubMed ID: 32956642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
    Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted histone deacetylase inhibition for cancer therapy.
    Vigushin DM; Coombes RC
    Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the development of assays suited for histone deacetylase inhibitor screening.
    Wegener D; Hildmann C; Schwienhorst A
    Mol Genet Metab; 2003; 80(1-2):138-47. PubMed ID: 14567963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of histone deacetylase inhibitors in lung cancer.
    Aparicio A
    Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors.
    Mork CN; Faller DV; Spanjaard RA
    Curr Pharm Des; 2005; 11(9):1091-104. PubMed ID: 15853658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
    Conley BA; Wright JJ; Kummar S
    Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.